

Study: ENGOT-ov85 / MK-2870-021

Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

MaNGO Sites list to be confirmed by Sponsor

Prov	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon	
GE	Genova	Ospedale San Martino	Serafina Mammoliti	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Istituto Nazionale dei Tumori	Mara Mantiero	
MO	Modena	AOU Policlinico	Roberto Sabbatini	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	
VA	Varese	Ospedale Del Ponte	Nicoletta Donadello	
GE	Genova	Ospedali Galliera	Nicoletta Provinciali	R
LC	Lecco	Ospedale Manzoni	Federica Villa	R

* MaNGO Principal Investigator to be defined

R = Back-up Site